EVolution Therapeutics was last week invited to pitch at SPARK Global in Berlin, where co-founder and CTO, Professor Andrew Devitt, had the honour of presenting the company’s vision for transforming the treatment of chronic inflammatory disease through RNA-enabled nanoparticle therapeutics.
The invitation reflects growing recognition of the company’s scientific progress and translational potential. Addressing an audience of translational researchers, investors, and global innovation leaders, Professor Devitt outlined EVolution Therapeutics’ foundations in immunology and inflammatory resolution, and its progress toward clinical translation. The presentation highlighted the potential of targeted immune reprogramming to move beyond passive disease management and toward active tissue repair.
EVolution Therapeutics’ presence at SPARK Global also reflects its roots in the UK innovation ecosystem. The company was part of the first cohort of SPARK The Midlands, supporting the transition of academic innovation into investable healthcare ventures and helping shape its commercial and translational strategy.
Pitching in Berlin marks another step in EVolution Therapeutics’ engagement with international partners, strategic collaborators, and investors as it advances toward first-in-human studies and expansion into broader inflammatory indications.